Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Okombo

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
ACS Infectious Diseases|December 12, 2018
Multistage Antiplasmodium Activity of Astemizole Analogues and Inhibition of Hemozoin Formation as a Contributor to Their Mode of ActionMalkeet Kumar, John Okombo, Dickson Mambwe, et al.
ACS Infectious Diseases|June 25, 2026
Using Unbiased Chemical Proteomics Approaches to Explore the Target Landscape of the Resistance Refractory 7-Azaindole MMV022224 in <i><i>Plasmodium falciparum</i></i>Aisha J Syed, Rachel Milne, Victoriano Corpas-Lopez, et al.
Nature|November 29, 2019
Structure and drug resistance of the Plasmodium falciparum transporter PfCRTJonathan Kim, Yong Zi Tan, Kathryn J Wicht, et al.
Plos Pathogens|October 29, 2024
A novel 4-aminoquinoline chemotype with multistage antimalarial activity and lack of cross-resistance with PfCRT and PfMDR1 mutantsLetícia Tiburcio Ferreira, Gustavo Capatti Cassiano, Luis Carlos Salazar Alvarez, et al.
Plos One|May 10, 2014
A genome wide association study of Plasmodium falciparum susceptibility to 22 antimalarial drugs in KenyaJason P Wendler, John Okombo, Roberto Amato, et al.
Journal of Medicinal Chemistry|February 23, 2021
Novel Antimalarial Tetrazoles and Amides Active against the Hemoglobin Degradation Pathway in <i>Plasmodium falciparum</i>Aloysus Lawong, Suraksha Gahalawat, John Okombo, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Shared Binding Site but Divergent Resistance Profiles Uncover Novel Resistance Mechanisms in <i>Plasmodium</i> HSP90 InhibitorsFu-Hsuan Ko, Amanda K Lukens, Mariana Laureano de Souza, et al.
Journal of Medicinal Chemistry|January 18, 2017
Antimalarial Pyrido[1,2-a]benzimidazoles: Lead Optimization, Parasite Life Cycle Stage Profile, Mechanistic Evaluation, Killing Kinetics, and in Vivo Oral Efficacy in a Mouse ModelKawaljit Singh, John Okombo, Christel Brunschwig, et al.
ACS Infectious Diseases|September 15, 2021
Prioritization of Molecular Targets for Antimalarial Drug DiscoveryBarbara Forte, Sabine Ottilie, Andrew Plater, et al.
Cell Reports|July 6, 2026
Plasmodium falciparum HSP90 inhibitors show divergent resistance despite a shared ATP-binding siteFu-Hsuan Ko, Amanda K Lukens, Mariana Laureano de Souza, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
ACS Infectious Diseases|December 12, 2018
Multistage Antiplasmodium Activity of Astemizole Analogues and Inhibition of Hemozoin Formation as a Contributor to Their Mode of ActionMalkeet Kumar, John Okombo, Dickson Mambwe, et al.
ACS Infectious Diseases|June 25, 2026
Using Unbiased Chemical Proteomics Approaches to Explore the Target Landscape of the Resistance Refractory 7-Azaindole MMV022224 in <i><i>Plasmodium falciparum</i></i>Aisha J Syed, Rachel Milne, Victoriano Corpas-Lopez, et al.
Nature|November 29, 2019
Structure and drug resistance of the Plasmodium falciparum transporter PfCRTJonathan Kim, Yong Zi Tan, Kathryn J Wicht, et al.
Plos Pathogens|October 29, 2024
A novel 4-aminoquinoline chemotype with multistage antimalarial activity and lack of cross-resistance with PfCRT and PfMDR1 mutantsLetícia Tiburcio Ferreira, Gustavo Capatti Cassiano, Luis Carlos Salazar Alvarez, et al.
Plos One|May 10, 2014
A genome wide association study of Plasmodium falciparum susceptibility to 22 antimalarial drugs in KenyaJason P Wendler, John Okombo, Roberto Amato, et al.
Journal of Medicinal Chemistry|February 23, 2021
Novel Antimalarial Tetrazoles and Amides Active against the Hemoglobin Degradation Pathway in <i>Plasmodium falciparum</i>Aloysus Lawong, Suraksha Gahalawat, John Okombo, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Shared Binding Site but Divergent Resistance Profiles Uncover Novel Resistance Mechanisms in <i>Plasmodium</i> HSP90 InhibitorsFu-Hsuan Ko, Amanda K Lukens, Mariana Laureano de Souza, et al.
Journal of Medicinal Chemistry|January 18, 2017
Antimalarial Pyrido[1,2-a]benzimidazoles: Lead Optimization, Parasite Life Cycle Stage Profile, Mechanistic Evaluation, Killing Kinetics, and in Vivo Oral Efficacy in a Mouse ModelKawaljit Singh, John Okombo, Christel Brunschwig, et al.
ACS Infectious Diseases|September 15, 2021
Prioritization of Molecular Targets for Antimalarial Drug DiscoveryBarbara Forte, Sabine Ottilie, Andrew Plater, et al.
Cell Reports|July 6, 2026
Plasmodium falciparum HSP90 inhibitors show divergent resistance despite a shared ATP-binding siteFu-Hsuan Ko, Amanda K Lukens, Mariana Laureano de Souza, et al.
Pageof 7